Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data

Jennifer Munday, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan and Michael S. Broder

ABSTRACT
Objective: Early initiation of antipsychotic treatment in schizophrenia is associated with improved outcomes. This study aimed to determine if initiation of long-acting injectable (LAI) antipsychotic treatment early in a new schizophrenia episode is associated with lower hospitalization rates and healthcare costs in a real-world setting.

Methods: This retrospective (January 1, 2007–June 30, 2016) cohort analysis used claims from Truven Health Analytics MarketScan Commercial, Medicaid, and Medicare Supplemental databases. In adults ≥18 years with a new episode of schizophrenia, two mutually exclusive cohorts were identified based on time from first recorded schizophrenia diagnosis date to first date of LAI initiation (index date): ≤1 year (early initiators) and >1 year (late initiators). Logistic and general linear regression models were performed to estimate adjusted hospitalization rate and healthcare costs in a 1-year follow-up, controlling patient demographic and clinical characteristics, insurance type, baseline all-cause hospitalizations and ED visits, and baseline psychiatric medication use.

Results: Of the subjects, 32% (n = 1388) initiated treatment early and 68% (n = 2978) initiated treatment later. In risk-adjusted models, all-cause hospitalization rates were 22.2% (95% CI = 19.9–24.6%) in early initiators and 26.9% (95% CI = 25.2–28.7%) in late initiators (p = .002). Of early initiators, 14.1% (95% CI = 12.3–16.1%) had a psychiatric hospitalization vs 19.2% (95% CI = 17.7–20.8%) of late initiators (p < .001). Adjusted psychiatric healthcare costs were significantly lower in early initiators compared with late initiators [mean (95% CI) = $21,545 (20,355–22,734) vs $24,132 (23,330–24,933)] (p < .001).

Conclusions: LAI initiation within 1 year of a new schizophrenia episode led to lower hospitalization rates and healthcare costs compared with LAI initiation more than 1 year after a new episode.

Introduction
Schizophrenia is a severe, disabling psychiatric disorder affecting less than 1% of the adult population in the US in a given year. The disease is characterized by positive symptoms (e.g. hallucinations, delusions, thought disorders, etc.), negative symptoms (e.g. flat affect, reduced feelings of pleasure, etc.), and cognitive symptoms. The estimated annual direct and indirect costs associated with schizophrenia were over $155 billion in 2013. Antipsychotic treatment is the cornerstone of management for patients with schizophrenia. Treatment guidelines published by the American Psychiatric Association recommend that first-episode schizophrenia be treated with oral antipsychotics and long-acting injectable (LAI) antipsychotics should be reserved for non-compliant patients with chronic schizophrenia.

Early initiation of antipsychotic treatment is associated with enhanced treatment response and prognosis, and reduced symptoms, relapse (i.e. hospitalizations, failure to respond, failure to improve, and psychotic exacerbations), healthcare resource use, and costs. However, even well-timed treatment is ineffective if patients are not adherent to their medications, and non-adherence is a significant problem in this disease. Rates of non-adherence to schizophrenia medication range from 34–81%, depending on the method of assessment and metric used, with many studies reporting rates around 50%. Previous studies have shown that antipsychotic non-adherence and drug formulation (e.g. oral vs LAI) predict an increased risk of hospitalization. Improving adherence results in reduced hospitalizations, and, in turn, healthcare savings. LAI formulations of antipsychotics are consistently shown to improve adherence compared to oral ones, despite a mixed impact on other health outcomes, such as relapse.

Early effective antipsychotic treatment, initiated at a stage of the illness during which psychosocial and structural damage may be less extensive, may be neuroprotective, and...
better adherence may lead to longer-term treatment effects. LAIs are increasingly being advocated for as early intervention or first-episode treatment for schizophrenia due to the superior adherence and other health benefits, such as improved functioning, associated with this formulation. In a search of the literature in 2018 using PubMed, there were no prior nationally representative studies that examined healthcare utilization or cost outcomes associated with timing of LAI initiation in patients with schizophrenia. Most studies that have assessed similar outcomes focused on differences between oral antipsychotic treatment and LAI treatment. Using insurance claims data, in this study, we examined whether patients with new episodes of schizophrenia who receive LAI treatment soon after a claims diagnosis have lower hospitalization rates and healthcare costs compared with patients who receive LAI treatment later, regardless of prior oral antipsychotic medication use. Given that LAIs have proven efficacious, we hypothesized that initiation of LAIs soon after a new schizophrenia episode would be superior to later LAI treatment initiation from an economic standpoint.

Methods

Data sources

Data from the Truven Health Analytics MarketScan Medicaid, commercial, and Medicare supplemental databases from January 1, 2007 to June 30, 2016 were used. The MarketScan Medicaid, commercial, and Medicare supplemental databases are Health Insurance Portability and Accountability Act (HIPAA)-compliant administrative claims databases. The Medicaid database contains the pooled healthcare experience of approximately 40 million Medicaid enrollees from multiple US states. It includes inpatient and outpatient services and outpatient prescription drug claims, as well as information on enrollment, long-term care, and other medical care. In addition to standard demographic variables such as age and sex, the database includes variables of particular value to researchers investigating Medicaid populations (such as ethnicity, maintenance assistance status, and Medicare eligibility). The names of the specific states are not available in the Truven Medicaid database.

The commercial data included medical encounters from ~65 million individuals and their dependents insured by employer-sponsored plans (i.e. non-Medicare eligible) in the US. Coverage was provided under a variety of fee-for-service, fully capitated, and partially capitated health plans, including preferred provider organizations, point of service plans, indemnity plans, and health maintenance organizations.

The Medicare supplemental data included about 5.3 million Medicare-eligible retired employees and their spouses with employer-sponsored Medicare supplemental plans in the US. Given the de-identified nature of the data used in the present study, informed consent was not required by HIPAA rules.

Study population and measures

In this study, we classified patients into two groups based on time from diagnosis to LAI initiation: ≤1 year (early) and >1 year (late). We identified patients with new episodes of schizophrenia in that they did not have a claim identified with schizophrenia in the preceding year. Patients were deemed to have a diagnosis of schizophrenia if they had at least one inpatient claim or at least two outpatient claims (on separate dates) for schizophrenia disorders. LAIs are increasingly being advocated for as early intervention or first-episode treatment for schizophrenia due to the superior adherence and other health benefits, such as improved functioning, associated with this formulation.

In this study, we classified patients into two groups based on time from diagnosis to LAI initiation: ≤1 year (early) and >1 year (late). We identified patients with new episodes of schizophrenia in that they did not have a claim identified with schizophrenia in the preceding year. Patients were deemed to have a diagnosis of schizophrenia if they had at least one inpatient claim or at least two outpatient claims (on separate dates) for schizophrenia disorders (International Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM] code: 295.xx, excluding 295.4x and 295.7x; or 10th revision [ICD-10-CM] code: F20x, excluding F20.81x). Therefore, we use the term “diagnosis” to denote that a patient met the claims-based criteria for a disease of interest (i.e. they received at least one inpatient claim or at least two outpatient claims for the disease).

Patients with schizophrenia were required to have (1) received an LAI in the study identification (ID) period between January 1, 2008 and June 30, 2015, and (2) a diagnosis date prior to or on the first date they received an LAI. The first date of the LAI was defined as the index date. To ensure that we were examining new episodes of care, patients were excluded if they had any medical claims for schizophrenia in the 1-year prior to their first diagnosis date found in the study ID period. To ensure we were examining initiation of an LAI for the first time in a given episode, patients with LAI use in the 1 year prior to the index date were excluded (see Figure 1).

We excluded patients who had a prescription for clozapine anytime during the study period, since clozapine is indicated for treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatments. We required patients to be ≥18 years on the index date and have continuous health plan enrollment for 1 year prior to (baseline) and after (follow-up) the index date. Due to incomplete data, we further excluded patients who had Medicare and Medicaid dual eligibility; had capitated insurance plans among Medicaid enrollees; lacked pharmacy coverage; or lacked mental health coverage during the entire study period.

Patient characteristics examined included demographic variables (e.g. age, sex, geographic region, race); insurance type; Charlson Comorbidity Index (CCI); number of chronic condition indicators; comorbidities; medication use (baseline and 1 year post-index); healthcare utilization at baseline, including all-cause and psychiatric office visits, inpatient hospitalizations, and emergency department visits; and costs at baseline, including all-cause and psychiatric total, inpatient, outpatient, and pharmacy. Healthcare costs were adjusted to 2016 US dollars.

Outcomes examined were (1) the number of all-cause and psychiatric inpatient hospitalizations over the 1-year follow-up period; and (2) all-cause and psychiatric total healthcare costs, including costs from inpatient, outpatient, and pharmacy settings over the 1-year follow-up period.

Statistical analysis

Descriptive statistics, including means, standard deviations, and relative frequencies and percentages for continuous and categorical data, respectively, were reported. Additionally, t-tests,
Chi-square, and Wilcoxon rank sum tests were performed depending on the type of measure. Logistic regression models were conducted to examine the association between each hospitalization and timing of LAI initiation; and linear regression models were conducted to examine the association between costs and timing of LAI initiation. Because the dichotomous variable cutoff of 1 year was arbitrary, we conducted sensitivity analyses using time between diagnosis and LAI as a continuous independent variable. We also ran models using the quadratic term of time from diagnosis to LAI to determine if any relationship was non-linear. All models were adjusted for baseline patient demographic and clinical characteristics (i.e. age, gender, mean CCI score, number of chronic conditions, psychiatric comorbidities, hyperlipidemia and hypertension), insurance type, all-cause hospitalizations and emergency department visits at baseline, and psychiatric medication use at baseline (including number of oral antipsychotic used). All data transformations and statistical analyses were performed using SAS version 9.4.

**Results**

**Baseline patient demographics, comorbidities, healthcare utilization, and costs**

Of the 117,792 patients with a claims-based diagnosis of schizophrenia from January 1, 2008 to June 30, 2015, 11,936 initiated an LAI after diagnosis (see Figure 2). The final study sample included 4366 patients (≥18 years) with new episodes of schizophrenia who initiated an LAI after the onset of the episode. As shown in Table 1, 31.8% (n = 1388) of patients initiated an LAI within 1 year following a new schizophrenia episode (early initiators), and 68.2% (n = 2978) initiated an LAI more than 1 year following a new schizophrenia episode (late initiators). Early initiators had a mean (SD) of 4.7 (3.9) months between the new schizophrenia episode and initiation of LAI treatment. Early initiators were younger, more likely to have commercial health insurance, had a lower burden of chronic diseases (e.g. obesity, type 2 diabetes, hyperlipidemia, hypertension), had a higher rate of major depressive disorders, and fewer used other psychiatric medications compared with late initiators (all p < .05) (Table 1).

As shown in Figure 3, early LAI initiators had fewer all-cause and psychiatric office visits [all-cause mean (SD) = 9.9 (15.6) vs 21.4 (34.6); psychiatric mean (SD) = 6.5 (13.3) vs 16.2 (32.5)], more all-cause and psychiatric inpatient hospitalizations [all-cause n (%) = 787 (56.7) vs 1325 (44.5); psychiatric n (%) = 691 (49.8) vs 1150 (38.6)], and more all-cause and psychiatric emergency department visits [all-cause n (%) = 661 (47.6) vs 1123 (37.7); psychiatric n (%) = 366 (26.4) vs 664 (22.3)] (all p < .05). All-cause costs did not significantly differ between early and late initiators. However, psychiatric costs were significantly lower after initiating an LAI among early initiators [mean (SD) = $20,531 (29,254) vs $24,855 (27,684); p < .001].

**Adjusted hospitalizations**

As shown in Table 2, CCI, number of chronic conditions, having at least one inpatient hospitalization, at least one emergency department visit, bipolar I disorder (BD-I) claim, MDD, anxiety, and taking an oral antipsychotic medication at baseline significantly increased patients’ risk of all-cause and psychiatric hospitalization in the 1-year follow-up period (all p < .05). Early initiation of LAI treatment, compared with late initiation, was associated with a 23% reduced risk of all-cause hospitalization and a 31% reduced risk of psychiatric hospitalization (all p < .05).

As shown in Figure 3, early LAI initiators had fewer all-cause and psychiatric hospitalizations compared with late LAI initiators in the 1-year follow-up period. Specifically, in risk-adjusted models, 22.2% (95% CI = 19.9–24.6%) of early initiators had an all-cause hospitalization compared with 26.9% (95% CI = 25.2–28.7%) of late initiators (p = .002); and 14.1% (95% CI = 12.3–16.1%) of early initiators had a psychiatric hospitalization compared with 19.2% (95% CI = 17.7–20.8%) of late initiators (p < .001).
Table 1. Patient demographics, comorbidities, and baseline medications.

<table>
<thead>
<tr>
<th>Time from diagnosis to LAI initiation</th>
<th>≤1 year</th>
<th>&gt;1 year</th>
<th>All patients</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>1388 (31.8)</td>
<td>2978 (68.2)</td>
<td>4366 (100.0)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Age, years, mean (SD) [median]</td>
<td>38.8 (15.8) [36]</td>
<td>41.3 (14.0) [41]</td>
<td>40.5 (14.7) [40]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Age, years, n (%)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–34</td>
<td>668 (48.1)</td>
<td>1146 (38.5)</td>
<td>1814 (41.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>35–44</td>
<td>197 (14.2)</td>
<td>534 (17.9)</td>
<td>731 (16.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>45–54</td>
<td>244 (17.6)</td>
<td>700 (23.5)</td>
<td>944 (21.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>55–64</td>
<td>212 (15.3)</td>
<td>502 (16.9)</td>
<td>714 (16.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>65+</td>
<td>67 (4.8)</td>
<td>96 (3.2)</td>
<td>163 (3.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>568 (40.9)</td>
<td>1213 (40.7)</td>
<td>1781 (40.8)</td>
<td>.905</td>
</tr>
<tr>
<td>Region, n (%)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>128 (9.2)</td>
<td>153 (5.1)</td>
<td>281 (6.4)</td>
<td>.698</td>
</tr>
<tr>
<td>Northeast</td>
<td>79 (5.7)</td>
<td>108 (3.6)</td>
<td>187 (4.3)</td>
<td>.409</td>
</tr>
<tr>
<td>South</td>
<td>165 (11.9)</td>
<td>144 (4.8)</td>
<td>309 (7.1)</td>
<td>.136</td>
</tr>
<tr>
<td>West</td>
<td>34 (2.4)</td>
<td>43 (1.4)</td>
<td>77 (1.8)</td>
<td>.222</td>
</tr>
<tr>
<td>Unknown (Medicaid)</td>
<td>982 (70.7)</td>
<td>2530 (85.0)</td>
<td>3512 (80.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>278 (20.0)</td>
<td>809 (27.2)</td>
<td>1087 (24.9)</td>
<td>.176</td>
</tr>
<tr>
<td>African American</td>
<td>555 (40.0)</td>
<td>1444 (48.5)</td>
<td>1999 (45.8)</td>
<td>.189</td>
</tr>
<tr>
<td>Other</td>
<td>149 (10.7)</td>
<td>277 (9.3)</td>
<td>426 (9.8)</td>
<td>.457</td>
</tr>
<tr>
<td>Unknown (Commercial/Medicare supplemen tal)</td>
<td>406 (29.3)</td>
<td>448 (15.0)</td>
<td>854 (19.6)</td>
<td>.202</td>
</tr>
<tr>
<td>Insurance type, n (%)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>982 (70.7)</td>
<td>2530 (85.0)</td>
<td>3512 (80.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Commercial</td>
<td>328 (23.6)</td>
<td>345 (11.6)</td>
<td>673 (15.4)</td>
<td>.007</td>
</tr>
<tr>
<td>Medicare supplemental</td>
<td>78 (5.6)</td>
<td>103 (3.5)</td>
<td>181 (4.1)</td>
<td>.115</td>
</tr>
<tr>
<td>Charlson comorbidity index, mean (SD)</td>
<td>0.9 (1.5)</td>
<td>1.0 (1.6)</td>
<td>1.0 (1.6)</td>
<td>.009</td>
</tr>
<tr>
<td>No. chronic conditions, mean (SD)</td>
<td>3.2 (2.1)</td>
<td>3.5 (2.2)</td>
<td>3.4 (2.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Bipolar I disorder, n (%)</td>
<td>520 (37.5)</td>
<td>1081 (36.3)</td>
<td>1601 (36.7)</td>
<td>.457</td>
</tr>
<tr>
<td>Major depressive disorder, n (%)</td>
<td>315 (22.7)</td>
<td>531 (17.8)</td>
<td>846 (19.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Anxiety, n (%)</td>
<td>442 (31.8)</td>
<td>862 (28.9)</td>
<td>1304 (29.9)</td>
<td>.051</td>
</tr>
<tr>
<td>Personality disorder, n (%)</td>
<td>176 (12.7)</td>
<td>405 (13.6)</td>
<td>581 (13.3)</td>
<td>.405</td>
</tr>
<tr>
<td>Substance abuse disorders, n (%)</td>
<td>497 (35.8)</td>
<td>1001 (33.6)</td>
<td>1498 (34.3)</td>
<td>.155</td>
</tr>
<tr>
<td>Somatic comorbidities, n (%)</td>
<td>669 (48.2)</td>
<td>1679 (56.4)</td>
<td>2348 (53.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Obesity</td>
<td>186 (13.4)</td>
<td>494 (16.6)</td>
<td>680 (15.6)</td>
<td>.007</td>
</tr>
<tr>
<td>Diabetes mellitus Type 2</td>
<td>244 (17.6)</td>
<td>701 (23.5)</td>
<td>945 (21.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>283 (20.4)</td>
<td>899 (30.2)</td>
<td>1182 (27.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>494 (35.6)</td>
<td>1256 (42.2)</td>
<td>1750 (40.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Oral antipsychotic medication, n (%)</td>
<td>990 (71.3)</td>
<td>2375 (79.8)</td>
<td>3365 (77.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Psychiatric medications, n (%)</td>
<td>881 (63.5)</td>
<td>2073 (69.6)</td>
<td>2954 (67.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Somatic medications, n (%)</td>
<td>510 (36.7)</td>
<td>1383 (46.4)</td>
<td>1893 (43.4)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

*Difference among the two groups.
Adjusted healthcare costs

As shown in Table 3, insurance type, CCI, number of chronic conditions, having at least one baseline ED visit, having at least one BD-I claim, personality disorder, substance abuse disorder, psychiatric medication use, and oral antipsychotic medication use were statistically significantly associated with all-cause costs among all patients with schizophrenia (all \( p < .05 \)). For example, having a claim for BD-I was associated with a $4306 increase in all-cause costs compared to patients without a claim for BD-I (\( p = .002 \)). Insurance type, number of chronic conditions, having at least one baseline inpatient hospitalization, having at least one baseline ED visit, BD-I claim, anxiety, personality disorder, psychiatric medication use, oral antipsychotic medication use, and LAI initiation status were statistically significantly associated with psychiatric costs among all patients with schizophrenia (all \( p < .05 \)).

As shown in Figure 4, early LAI initiators had lower all-cause and psychiatric healthcare costs compared with late LAI initiators in the 1-year follow-up period. Specifically, in risk-adjusted models, early LAI initiators had lower, although not statistically significant (\( p = .303 \)), all-cause costs compared with late initiators [adjusted mean (95% CI) = $34,878 (32,759–36,798) vs $36,241 (34,813–37,668)]. Psychiatric healthcare costs were statistically significantly lower in early initiators compared with late initiators [adjusted mean (95% CI) = $21,545 (20,355–22,734) vs $24,132 (23,330–24,933); \( p < .001 \)].

Sensitivity analyses

Models were repeated with time to LAI initiation as a continuous variable. Results were not significant in three out of the four models (\( p \)-value of the time between diagnosis and LAI in the model with all-cause cost as the outcome variable: \( p = .467 \); psychiatric-cost: \( p = .429 \); all-cause hospitalization: \( p = .224 \); psychiatric hospitalization: \( p = .043 \)). Using the
J. MUNDAY ET AL.

The presence of a non-linear relationship (p-value of the quadratic term in the model with all-cause cost as the outcome variable: \( p = .005 \); psychiatric cost: \( p = .0003 \); all-cause hospitalization: \( p = .048 \); psychiatric hospitalization: \( p = .01 \)).

### Table 3. All-cause and psychiatric healthcare costs in the 1-year follow-up period (adjusted to $2016).

<table>
<thead>
<tr>
<th>Age group</th>
<th>All-cause costs in post 1-year period</th>
<th>Total psychiatric-specific costs in post 1-year period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimate (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>18 to 34 vs 55+</td>
<td>-$3067 (-7023–890)</td>
<td>.12</td>
</tr>
<tr>
<td>35 to 44 vs 55+</td>
<td>-$7347 (-11559–3135)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>45 to 54 vs 55+</td>
<td>-$4845 (-8687–1003)</td>
<td>.013</td>
</tr>
<tr>
<td>Female vs Male</td>
<td>-$1607 (-4193–980)</td>
<td>.223</td>
</tr>
</tbody>
</table>

*Costs of claims with a primary diagnosis of any mental disorder (ICD-9-CM: 290.xx-311.xx; ICD-10-CM code: F01.xx-F99.xx), and costs of mental health-related treatments.

*Adjusted by baseline characteristics (age group, gender, insurance type, Charlson comorbidity index, no. of chronic conditions (HCUP), baseline hypertension, baseline hyperlipidemia, baseline comorbidities (including type 1 BD, MDD, anxiety, personality disorder, substance abuse disorder), baseline inpatient hospitalization, baseline psychiatric medication use, and number of baseline oral antipsychotic medications used.

### Figure 4. Risk adjusted* all-cause and psychiatric** healthcare costs in the 1-year follow-up period ($2016). Early LAI initiators had lower all-cause and psychiatric healthcare costs compared with late LAI initiators in the 1-year follow-up period.

*Adjusted by baseline characteristics (age group, gender, insurance type, Charlson comorbidity index, no. of chronic conditions (HCUP), baseline hypertension, baseline hyperlipidemia, baseline comorbidities (including type 1 BD, MDD, anxiety, personality disorder, substance abuse disorder)), baseline inpatient hospitalization, baseline psychiatric medication use, and number of baseline oral antipsychotic medications used.

\[^{**}\]Costs of claims with a primary diagnosis of any mental disorder (ICD-9-CM: 290.xx-311.xx; ICD-10-CM code: F01.xx-F99.xx), and costs of mental health-related treatments.

### Discussion

This is the first, large retrospective longitudinal study to examine the effects of timing of LAI initiation in patients with new episodes of schizophrenia on hospitalization rates and healthcare costs in a real-world setting. Patients who initiated LAIs within 1 year following a new claim for schizophrenia had lower hospitalization rates and healthcare costs in the 1-year follow-up period than patients who initiated LAIs more than 1 year after such a claim, regardless of whether or not they had used oral antipsychotics prior to the LAI. Almost 32% of patients in our sample initiated a LAI within 1 year following a new episode of schizophrenia (early initiators), and 68% initiated a LAI more than 1 year after a new episode of schizophrenia (late initiators). All-cause hospitalization rates were significantly lower among early initiators, as over 22% of early initiators had at least one all-cause hospitalization compared with almost 27% of late initiators in the 1-year follow-up period. Also, psychiatric costs were significantly lower among early initiators compared to late initiators in the 1-year follow-up period (mean of $21,545 vs $24,132). The study included a wide variety of patient types, and included commercially insured, Medicare, and Medicaid patients.

Our finding that early initiation of LAIs was associated with lower all-cause hospitalization rates compared with later initiation adds to the literature on the benefits of LAIs on healthcare outcomes. Previous studies have examined differences in healthcare outcomes in patients with schizophrenia treated with LAIs vs oral antipsychotics, and have shown greater benefits associated with LAIs. Specifically, compared with oral antipsychotics, LAIs have been shown to more effectively enhance medication adherence and...
personal and social functioning\(^3\)\(^9\); increase remission rates\(^3\)\(^9\); may provide continual neuroprotection\(^3\)\(^5\); and reduce clinical symptoms\(^3\)\(^9\) and risk of relapse\(^4\)\(^2\). Also, several European studies have shown that LAIs compared with oral antipsychotics were associated with reduced risk of relapse\(^3\)\(^9\),\(^4\)\(^3\) and fewer hospitalizations\(^4\)\(^4\). For example, in a nationwide Finnish cohort study with 2588 patients hospitalized for the first time with a schizophrenia diagnosis between 2000 and 2007, analyses indicated that the risk of hospitalization and medication discontinuation was significantly lower for patients who received LAIs compared with patients who received oral medications of the same compounds\(^3\)\(^3\)\(^3\).

Early initiation of LAIs provided benefits associated with this formulation earlier in the course of the disease, such as increased antipsychotic adherence and reduced risk of relapse, which likely led to downstream reduced healthcare resource utilization and cost savings. In fact, several studies have concluded that schizophrenia-related costs are lower with LAIs vs oral antipsychotics\(^4\)\(^1\),\(^4\)\(^5\)–\(^4\)\(^8\), and a systematic review of cost-effectiveness studies deduced that LAIs are cost-effective as first-line treatment for schizophrenia\(^4\)\(^9\).

**Study limitations**

This study has limitations. First, we do not have information about the patients’ schizophrenia-related disease severity, or the length of time they had been living with the disease; we do not know if the first diagnosis (new episode) in our data-set is the true initial diagnosis. However, the new schizophrenia episode likely represents new interactions with the healthcare system, as patients were excluded if they had any medical claims for schizophrenia in the 1 year prior to their first diagnosis date found in the study ID period. Second, we arbitrarily set the distinction between early vs late LAI initiation at 1 year. We chose this threshold because it is a common one, because we believed we would have adequate data to answer the question, and because dichotomized results are easier to explain. Our sensitivity analysis suggests that the relationship between time from schizophrenia diagnosis to LAI initiation and the outcome measures is not linear, making any dichotomization potentially problematic. Further research is needed to explore whether there are inflection points at which the impact of not initiating LAI becomes more or less pronounced. Third, claims data used are generated for reimbursement, not research, and coding errors, misclassification, diagnostic uncertainty, and/or omissions could affect the reliability of the findings. Specifically, we could not clinically validate any diagnoses in this study due to privacy regulations, as data were de-identified. Nevertheless, health insurance claims data remain a valuable source of information because they contain a large and valid sample of patient characteristics in a real-world setting; and insurance claims are often used to examine healthcare utilization, cost, and even quality of care. Fourth, we could not control for physician prescribing practices or other patient characteristics, such as underlying symptoms and socioeconomic factors. Ideally, we would like to replicate this study using a data source that has longer history, as the attrition rate in the claims dataset used for this study hindered our ability to do so. For a variety of reasons, only \(\sim 10\)% of the schizophrenia population initiates LAI treatment. Patients may resist LAIs because of stigma, fear of injections, time constraints, and costs\(^5\)\(^0\)–\(^5\)\(^2\). Clinicians may be reluctant to prescribe LAIs due to their beliefs about side-effects, lack of evidence of superior efficacy, and lack of practical knowledge about their use\(^5\)\(^0\). To lower barriers to doctors’ prescription and patients acceptance of LAIs, a substantial change in the general attitude towards LAIs as a treatment option may be required\(^5\)\(^3\).

**Conclusions**

These results provide supportive evidence of potential benefits associated with the use of LAIs early in the course of schizophrenia treatment. Specifically, our findings indicate that early use may have beneficial effects on treatment management, adherence, relapse rates, and other outcomes, which lead to reduced hospitalization rates and healthcare costs. Future research should evaluate outcomes associated with differential treatment in first-episode schizophrenia vs new episodes that occur farther along in the disease course. Clinicians have a vital role in educating patients with schizophrenia and their caregivers about treatment options, including LAI treatment, and offering this option where appropriate in this critical period of their disease management.

**Transparency**

**Declaration of funding**

Funding for the study was received from Otsuka Pharmaceutical Development and Commercialization, Inc. and Lundbeck.

**Declaration of financial/other relationships**

Greene is an employee of Otsuka Pharmaceutical Development and Commercialization, Inc. Hartry is an employee of Lundbeck. Broder, Chang, Munday, and Yan are employees of PHAR, LLC, which was paid by Otsuka and Lundbeck to perform the research described in this manuscript. Peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no other relevant financial relationships to disclose.

**Acknowledgments**

No assistance in the preparation of this article is to be declared.

**ORCID**

Ann Hartry http://orcid.org/0000-0001-8649-1311

**References**


